Skip to content


  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Add this article to your Facebook page
  • Email this article
  • View or print a PDF of this page
  • Share further
  • Add this article to your Pinterest board
  • Add this article to your Google page
  • Share this article on Reddit
  • Share this article on StumbleUpon
  • Bookmark this page

The connected patient


Maike Telgheder and Holger Alich


3 February 2015

Kevin Deane and Frazer Bennett, technology and life sciences experts at PA, are quoted in Handelsblatt. The article examines how pharmaceutical firms are considering how to use digital solutions for more effective treatments.

The article outlines how digital health is a fast-growing market, expected to triple until 2020, and how medical practitioners could potentially monitor a patient’s condition – even if the patient has forgotten to take their medicine.

In the piece, Kevin comments: "Many pharma companies are currently working on strategies beyond pure drug development and how to make treatments more effective by increasing drug adherence." Kevin’s comments come on the back of talks with big pharma companies about using the health patch PA has developed. For example, the patch, attached to the skin, has a sensor to monitor whether medicine is taken by the patient.

Technology expert Frazer then adds how a big issue for them was to achieve a reasonable target price of patch: "We could prove a production cost of 50 US cents, on a production run of 200m units a year." This keeps the application of this wearable device on the radar of various pharma companies.

By using this website, you accept the use of cookies. For more information on how to manage cookies, please read our privacy policy.